Network pharmacology: curing causal mechanisms instead of treating symptoms

发布时间：2025-11-17 16:02

取得Cisco Certified Network Associate认证，强化网络技术 #生活技巧# #工作学习技巧# #工作技能认证#

Review

Actions

. 2022 Feb;43(2):136-150.

doi: 10.1016/j.tips.2021.11.004. Epub 2021 Dec 9.

Affiliations

PMID: 34895945 DOI: 10.1016/j.tips.2021.11.004

Free article

Review

Network pharmacology: curing causal mechanisms instead of treating symptoms

Cristian Nogales et al. Trends Pharmacol Sci. 2022 Feb.

Free article

Abstract

For complex diseases, most drugs are highly ineffective, and the success rate of drug discovery is in constant decline. While low quality, reproducibility issues, and translational irrelevance of most basic and preclinical research have contributed to this, the current organ-centricity of medicine and the 'one disease-one target-one drug' dogma obstruct innovation in the most profound manner. Systems and network medicine and their therapeutic arm, network pharmacology, revolutionize how we define, diagnose, treat, and, ideally, cure diseases. Descriptive disease phenotypes are replaced by endotypes defined by causal, multitarget signaling modules that also explain respective comorbidities. Precise and effective therapeutic intervention is achieved by synergistic multicompound network pharmacology and drug repurposing, obviating the need for drug discovery and speeding up clinical translation.

Keywords: biomarkers; cancer; cardiovascular; disease modules; network pharmacology.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests No interests are declared.

Cited by

The molecular and network mechanisms of antilipidemic potential effects of Ganfule capsules in nonalcoholic fatty liver disease.

Pan Y, Qiao L, Zhang Y, Sooranna SR, Huang D, Ou M, Xu F, Chen L, Huang D.Pan Y, et al.Heliyon. 2024 Jul 10;10(14):e34297. doi: 10.1016/j.heliyon.2024.e34297. eCollection 2024 Jul 30.Heliyon. 2024.PMID: 39113948Free PMC article.

New opportunities and challenges of natural products research: When target identification meets single-cell multiomics.

Zhu Y, Ouyang Z, Du H, Wang M, Wang J, Sun H, Kong L, Xu Q, Ma H, Sun Y.Zhu Y, et al.Acta Pharm Sin B. 2022 Nov;12(11):4011-4039. doi: 10.1016/j.apsb.2022.08.022. Epub 2022 Aug 27.Acta Pharm Sin B. 2022.PMID: 36386472Free PMC article.Review.

Network Pharmacology and Transcriptomics to Explore the Pharmacological Mechanisms of 20(S)-Protopanaxatriol in the Treatment of Depression.

Guo X, Su L, Shi M, Sun L, Chen W, Geng J, Li J, Zong Y, He Z, Du R.Guo X, et al.Int J Mol Sci. 2024 Jul 10;25(14):7574. doi: 10.3390/ijms25147574.Int J Mol Sci. 2024.PMID: 39062817Free PMC article.

Mechanisms of Yiai Fuzheng formula in the treatment of triple-negative breast cancer based on UPLC-Q-Orbitrap-HRMS, network pharmacology, and experimental validation.

Li R, Ke H, Liu P, Yang Q, Li Y, Ke L, Wang X, Wu C, Zhang Y.Li R, et al.Heliyon. 2024 Aug 20;10(17):e36579. doi: 10.1016/j.heliyon.2024.e36579. eCollection 2024 Sep 15.Heliyon. 2024.PMID: 39319146Free PMC article.

Prediction of the mechanism for the combination of diallyl trisulfide and cisplatin against gastric cancer: a network pharmacology study and pharmacological evaluation.

Lv H, Jia X, Yang H, Zhu X, Zhao Z, Jiang X.Lv H, et al.Front Pharmacol. 2023 Oct 30;14:1269895. doi: 10.3389/fphar.2023.1269895. eCollection 2023.Front Pharmacol. 2023.PMID: 37964870Free PMC article.